Section III: Life Science Patents in Practice



David Korn, PhRMA September 23, 2020

π̈́

Patents Enable Biopharmaceutical Companies to Invest in the Lengthy, Costly and Uncertain R&D Process for New Medicines

From drug discovery through FDA approval, developing a new medicine typically takes 10 to 15 years and costs an average of \$2.6 billion, more than double the cost just a decade ago.¹

Basic Research	Drug Discovery	Pre- Clinical		Clinical Trials				FDA Review		Post-Approval Research & Monitoring
				Phase I	Phase II	Phase III				Phase IV
			IND SUBMITTED	make	han 12% of r e it through ti pproval proc	he FDA	NDA/BLA SUBMITTED		FDA APPROVAL	1 FDA-Approved Medicine

Key: IND= Investigational New Drug Application, NDA= New Drug Application, BLA= Biologics License Application


The typical science-based business startup is not unlike a long-range multistage rocket mission: Each stage must fire perfectly for the next step of the mission to begin. If any stage fails to execute, the entire mission fails. Even investors with a high tolerance for risk are deterred by the uncertainty of the risk.

"

MIT PROFESSOR ANDREW W. LO AND HARVARD PROFESSOR GARY P. PISANO²

1. PhRMA adaptation of DiMasi J et al. (2016). Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs. Journal of Health Economics. 47:20-33. Retrieved from: <u>https://www.ncbi.nlm.nih.gov/pubmed/26928437</u> 2. Lo, A. et al. (2016). Lessons from Hollywood: A New Approach to Funding. R&D. MIT Sloan Management. Review. 47-57. Retrieved from: https://dialnet.unirioja.es/servlet/articulo?codigo=5724539.

Patents Incentivize Different Forms of Biopharmaceutical Innovation; a Medicine May Be Covered by Multiple Types of Patents



Post-FDA Approval Medical Advances Take Many Forms and Require Additional Costly and Time-Consuming Research and Development

Research and development of new forms, new uses, and combination therapies requires significant investments of time and resources. These innovations can lead to critical benefits for patients, including new treatment options, and new and improved forms or methods of delivery can be more convenient and improve adherence.

Key incentives—including regulatory data protection and patents—to promote investment in additional research on existing medicines to explore new medical advances are critical. While a new innovation can be patented, provided it meets the standards, the new patent only covers the new innovation, not the original or prior version of the medicine.

Innovative forms are held to the same rigorous FDA standards as the initial medicine approved by FDA and must undergo testing, including in many cases Phase III trials.

Public-Private Collaboration Fuels the US Biopharmaceutical Ecosystem

Exchange of Scientific Knowledge



identify who has the right assets and intellectual capital to bring together. The security that patents provide is fundamental to encouraging collaboration and investment, and incentivizing ongoing research and development into new medicines for patients.

on and advance basic science research into safe and effective treatments that can be made available to patients.

industry, academic, and government scientists are encouraged

to collaborate on research questions, the biopharmaceutical

industry's ability to take the necessary risks is required to build